Lead in the Billion-Dollar Weight-Loss Pill Market! Eli Lilly Keeps Rival Novo Nordisk at Bay!
Reading Time: 3 minutes
Market Dominance in Seniors: Eli Lilly captures 70% of approximately 700,000 Medicare patients newly treated with GLP-1 medications since July 2026 Pill Success & Capacity Expansion: One third of new patients using weight-loss pills opt for Foundayo, new location in Houston to secure production Oncology Approval: FDA approves combination therapy of Inluriyo and Verzenio for breast cancer after doubling survival chances "This is exactly what we had hoped for,” summarized Eli Lilly (LLY) CEO Dave Ricks in an interview with US broadcaster...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
